Conditions: Malignant Neoplasms of Thyroid and Other Endocrine Glands; Anaplastic Thyroid Carcinoma; Poorly Differentiated Thyroid Cancer
Interventions: Drug: Nab-paclitaxel - INDUCTION COHORT; Drug: Paclitaxel - INDUCTION COHORT; Drug: Vemurafenib - COHORT 1; Drug: Cobimetinib - COHORT 1; Drug: Atezolizumab - COHORT 1; Drug: Bevacizumab - COHORT 3; Drug: Nab-paclitaxel - COHORT 4; Drug: Paclitaxel - COHORT 4; Drug: Cobimetinib - COHORT 2; Drug: Atezolizumab - COHORT 2; Drug: Atezolizumab - COHORT 3; Drug: Atezolizumab - COHORT 4
Sponsors: M.D. Anderson Cancer Center; Genentech, Inc.
Not yet recruiting - verified June 2017
http://ift.tt/2rZvJXL
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου